@DiandaGP

QFB Doctorado en Inmunología

Joined November 2009
  • Tweets5.5K
  • Following70
  • Followers46
44Media
El 15 de febrero enmarca el Dis Internacional del Cáncer Infantil y nos señala sobre la relevancia de detectar a tiempo y ofrecer mejores estrategias de tratamientos para niñas, niños y adolescentes. La leucemia linfobástica aguda es el principal tipo de cancer infantil.
1
24
Diana Portales-Pérez retweeted
Gaceta Médica de México
@GacetaMedicaMexOct 6
🤖 La #InteligenciaArtificial está transformando la #Salud En #GacetaMedicaMex estamos preparando un número especial sobre la #IA en Salud y nos encantaría conocer tu #investigación ¡Envíanos tus artículos originales, fecha límite el 31 de octubre! 👇 gacetamedicademexico.com/fil…
7
12
409
Diana Portales-Pérez retweeted
NEJM
@NEJMOct 6
In ER-positive, HER2-negative advanced breast cancer, giredestrant, an ER degrader and full ER antagonist, plus everolimus led to longer progression-free survival than standard endocrine therapy–everolimus; safety was similar. Full phase 3 evERA Breast Cancer trial results and Research Summary: nej.md/47ryfbF
This image contains an excerpt from the Research Summary "Giredestrant plus Everolimus in Advanced Breast Cancer" published in the New England Journal of Medicine. It includes patient statistics, with a focus on median age and gender percentage. Two treatment comparisons are depicted: Giredestrant plus Everolimus versus Standard Endocrine Therapy plus Everolimus. The treatments are illustrated with labeled medication containers. A prompt to read the full Research Summary at NEJM.org sits at the bottom.

ALT This image contains an excerpt from the Research Summary "Giredestrant plus Everolimus in Advanced Breast Cancer" published in the New England Journal of Medicine. It includes patient statistics, with a focus on median age and gender percentage. Two treatment comparisons are depicted: Giredestrant plus Everolimus versus Standard Endocrine Therapy plus Everolimus. The treatments are illustrated with labeled medication containers. A prompt to read the full Research Summary at NEJM.org sits at the bottom.

4
28
1
79
18,207
Diana Portales-Pérez retweeted
Cell Metabolism@Cell_MetabolismOct 6
The interplay between the microbiome and immune cells in metabolic homeostasis and disease dlvr.​it/TVpFy1
19
69
5,016
Diana Portales-Pérez retweeted
Hospital Juárez de México@HospitalJuarezMOct 5
El abordaje del sobrepeso y la obesidad va más allá del peso: abarca aspectos metabólicos, mecánicos, mentales y sociales Conoce el protocolo del PRONAM para una detección, clasificación y tratamiento integral. Consulta el protocolo completo en: pronamsalud.csg.gob.mx
31
88
2,630
Diana Portales-Pérez retweeted
Eric Topol
@EricTopolOct 5
A "normal" mammogram interpreted by AI can accurately forecast high-risk of breast cancer in the next 5 years. Approved by FDA, now becoming available. But it should be free and part of every mammogram readout. Front page @nytimes today, by @RoniNYTimes gift link nytimes.com/2026/10/01/well/…
21
105
9
366
30,188
Diana Portales-Pérez retweeted
Milstein
@MilsteinmAbOct 5
En el 2001, la primer editorial de la revista @NatRevImmunol mencionaba: "todavía no sabemos cómo estimular al sistema inmune para eliminar el cáncer". 25 años después, una nueva editorial reconoce que ese avance llegó. Estos son los tres tipos de inmunoterapia que hoy están en la clínica. 1- INHIBIDORES DE CHECKPOINT Los checkpoints son frenos naturales del sistema inmune: moléculas como CTLA-4 y PD-1 que evitan que los linfocitos T ataquen de más. Los tumores los aprovechan para esconderse. Los inhibidores son anticuerpos que bloquean esos frenos, así los linfocitos que ya están cerca del tumor pueden seguir atacando. Ipilimumab, anti-CTLA-4, fue el primero aprobado, en 2011 para melanoma. Los anti-PD-1 y anti-PD-L1, como pembrolizumab y nivolumab, llegaron después. Por esto, James Allison y Tasuku Honjo recibieron el Nobel de Medicina en 2018. 2- CÉLULAS CAR-T Se toman linfocitos T del propio paciente, se les incorpora en el laboratorio un receptor sintético (el CAR, chimeric antigen receptor) que reconoce una proteína de la superficie de las células tumorales, se multiplican y se reinfunden. Son células vivas que funcionan como medicamento. La primera aprobada por la FDA fue Kymriah, en 2017, para leucemia linfoblástica aguda en chicos y jóvenes. Hoy tiene indicaciones en leucemia, linfoma y mieloma. Sus límites son el costo y efectos secundarios graves, como el síndrome de liberación de citoquinas. 3- VACUNAS CONTRA EL CÁNCER No son las vacunas preventivas de siempre. Son terapéuticas: buscan entrenar al sistema inmune para atacar un tumor que ya existe. Son vacunas personalizadas de neoantígenos, diseñadas para cada paciente a partir de las mutaciones de su tumor. La vacuna de melanoma de ARNm que $MRNA y $MRK anunciaron en agosto de 2026 es el único ejemplo actual que haya superado un ensayo de fase III. Esperemos que en la editorial de los 50 años, los avances hayan sido suficientes para que el cáncer sea un problema resuelto. doi.org/10.1038/s41577-026-0…
1
6
21
980
Diana Portales-Pérez retweeted
Science Magazine
@ScienceMagazineOct 5
CD1 proteins on so-called antigen-presenting cells display lipids from pathogens to T cells to drive protective immune responses, but they also trigger skin inflammation in response to some lipids. Learn more: scim.ag/4rK8tc7 @NewsfromScience
Illustration of an immune reaction to urushiol. The first panel shows an inflammatory rash on hands and forearms. An inset illustration shows a zoomed-in view of a T cell and an antigen-presenting cell making contact, while surrounded by smaller lipid molcules. Another inset zooms in on the contact between the cells, showing how a lipid fits into the CD1 protein on the antigen-presenting cell. A T cell receptor can be triggered by touching CD1 and the lipid it holds, but sometimes the lipid is hidden due to where it sits in the protein, so only CD1 makes contact.

ALT Illustration of an immune reaction to urushiol. The first panel shows an inflammatory rash on hands and forearms. An inset illustration shows a zoomed-in view of a T cell and an antigen-presenting cell making contact, while surrounded by smaller lipid molcules. Another inset zooms in on the contact between the cells, showing how a lipid fits into the CD1 protein on the antigen-presenting cell. A T cell receptor can be triggered by touching CD1 and the lipid it holds, but sometimes the lipid is hidden due to where it sits in the protein, so only CD1 makes contact.

4
51
3
260
57,371
Diana Portales-Pérez retweeted
Cell Reports@CellReportsSep 29
Antigen-specific regulatory T cells eliminate cognate CD4 effector T cells through perforin, granzyme B, and Bim dlvr.it/TVhcHd

Antigen-specific regulatory T cells eliminate cognate CD4 effector T cells through perforin,...

Ye et al. describe a synthetic-lethality-analogous killing model. Shared peptide-MHC-II co-activation enables Treg perforin-granzyme B cytotoxicity; responder Bim confers susceptibility in vitro and...

cell.com
3
19
95
8,470
TKTL1-driven #Glycolysis increases lactate and promotes #Immunosuppressive dendritic-cell signaling in #HCC. Targeting the TKTL1–HIF-1α–HK2 axis and lactate reprograms the #TumorMicroenvironment to enhance PD-1 blockade. #STTT #OpenAccess: doi.org/10.1038/s41392-026-0…
Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation

ALT Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation

5
8
431
Diana Portales-Pérez retweeted
Trends in Immunology@TrendsImmunoSep 29
Coupling and uncoupling cell cycle and metabolism in CD8+ T cells dlvr.it/TVhMB2 #immunology
1
60
2
172
8,155
Diana Portales-Pérez retweeted
Mitochondrial Medicine@Mito_TherapySep 27
Good morning mito-folks, don't miss this rich selection of papers related to #mitochondrialmedicine presorted by @Bims_BiomedNews biomed.news/bims-mitmed/2026… The predicted interactome of the human mitochondrial proteome
4
12
1
38
3,145
Diana Portales-Pérez retweeted
Gustavo Portales@R2portalesSep 27
1
10
Diana Portales-Pérez retweeted
Cell Reports@CellReportsSep 25
Increased extracellular fluid viscosity drives M2-like macrophage polarization to promote breast cancer progression and immunotherapy resistance dlvr.it/TVdznq

Increased extracellular fluid viscosity drives M2-like macrophage polarization to promote breast...

Zhang et al. demonstrate that increased extracellular fluid viscosity promotes immunosuppressive M2-like macrophage polarization through integrin/FAK-STAT3 signaling and cytoskeletal remodeling. This...

cell.com
7
1
25
5,135
Diana Portales-Pérez retweeted
Keita Masui
@keita_masuiSep 25
抗がん剤をつないだ薬は、細胞に飲み込まれて初めて効く――その前提が外れた。 抗体薬物複合体（ADC）は、がんの目印に取りつき、細胞の中に飲み込まれてから積み荷の抗がん剤を放つ。この仕組みが成り立つ目印は、全体の1割ほどしかない。飲み込まれにくい目印だと、薬が外れて体から早く消えてしまう。 Zhibo Liu氏らのチームが示したのが、飲み込まれなくても薬を放つ設計。目印の受け皿にはまった瞬間、その内側にあるアミノ酸が自ら薬を切り離す。鍵が鍵穴に入ると、鍵穴の側が荷物を受け取る形。 がんの周りの細胞に出る目印（FAP）で試すと、腫瘍の中の抗がん剤の量は従来型の5.9倍。腫瘍と肝臓の濃度比は55倍になり、使える最大量も増えた。複数の腫瘍モデルで、ほぼ完全に消えたという。 飲み込ませて放つ、から、触れて放つ、へ。狙える的が、1割の外へ広がるかもしれない。 ※動物の腫瘍モデルでの結果で、ヒトでの治療効果は未検証。患者由来の検体では、目印の検出に成功した段階。 出所：Nature（2026/8/26）A binding-to-release strategy for targeted anticancer drug delivery nature.com/articles/s41586-0… @Nature

A binding-to-release strategy for targeted anticancer drug delivery

Nature - A binding-to-release drug conjugate strategy enables targeted payload release without cellular internalization, improving tumour specificity, efficacy and expanding therapeutic targets...

nature.com
1
33
3
152
17,216
Diana Portales-Pérez retweeted
Maria Konovalenko
@mkonovalenkoSep 24
Immune cells fighting a long infection or cancer eventually burn out and stop working — a big reason some cancers escape the immune system entirely. Folks from St. Jude found a single gene acting as the burnout switch, and turning it off let exhausted immune cells snap back into fighting shape, dramatically improving survival in mice with cancer and chronic infections. nature.com/articles/s41586-0…

Targeting ZMYND8 unleashes IL-2 signalling to override T cell exhaustion

Nature - ZMYND8 suppresses IL-2R–STAT5 signalling by inhibiting p300-mediated transcriptional activation of Il2ra to enforce CD8+ T cell terminal exhaustion, and its deletion boosts...

nature.com
3
29
1
122
6,435
Diana Portales-Pérez retweeted
News from Science
@NewsfromScienceSep 24
A new generation of radiotherapies promises a more targeted attack on cancer. Learn more on #WorldCancerResearchDay: scim.ag/3KGrg6K
An illustration shows how antibodies, peptides, and other molecules can be used to target the radioisotope to a specific type of cancer cell, which it kills by damaging its DNA. Alpha particle emitters affect a smaller number of cells (5 to 10 per particle) but do more damage, causing double-strand DNA breaks, whereas beta emitter particles affect a wider area (75 to 100 cells per particle) but cause only single-strand DNA breaks.

ALT An illustration shows how antibodies, peptides, and other molecules can be used to target the radioisotope to a specific type of cancer cell, which it kills by damaging its DNA. Alpha particle emitters affect a smaller number of cells (5 to 10 per particle) but do more damage, causing double-strand DNA breaks, whereas beta emitter particles affect a wider area (75 to 100 cells per particle) but cause only single-strand DNA breaks.

4
25
3
114
12,623
Diana Portales-Pérez retweeted
Milstein
@MilsteinmAbSep 22
Lograron convertir células de glioblastoma en células presentadoras de antígeno @CellPressNews El glioblastoma es un tumor "frío" que presenta pocos antígenos y evade al sistema inmune, por eso es difícil de abordar con inmunoterapia. Con un screen de CRISPR encontraron cuatro factores de transcripción que alcanzan para convertir células de glioblastoma en células dendríticas. En varios modelos de ratón eso generó inmunidad antitumoral sistémica y duradera, y sumó efecto a los inhibidores de checkpoint. Es en ratones, así que falta. Pero es por acá 👍 doi.org/10.1016/j.xcrm.2026.…
5
40
2
198
7,542
Diana Portales-Pérez retweeted
NEJM
@NEJMSep 22
Among children with high-risk B-cell acute lymphoblastic leukemia, two cycles of blinatumomab led to a higher 4-year event-free survival than two cycles of chemotherapy (83.0% vs. 70.3%), with a lower risk of serious infection. Full phase 3 AIEOP-BFM ALL 2017 trial results and Research Summary: nej.md/4dBfwOk
This image contains an excerpt from the Research Summary "Blinatumomab as Chemotherapy Replacement in Pediatric ALL." It includes a diagram of how Blinatumomab works as a bispecific T-cell engager directed at CD19 on B cells. Statistics are shown: 709 children, age range of <1 to 17 years. Two treatment groups are compared: Blinatumomab (N=358) and intensive chemotherapy (N=351). A prompt to read the full Research Summary at NEJM.org sits at the bottom.

ALT This image contains an excerpt from the Research Summary "Blinatumomab as Chemotherapy Replacement in Pediatric ALL." It includes a diagram of how Blinatumomab works as a bispecific T-cell engager directed at CD19 on B cells. Statistics are shown: 709 children, age range of <1 to 17 years. Two treatment groups are compared: Blinatumomab (N=358) and intensive chemotherapy (N=351). A prompt to read the full Research Summary at NEJM.org sits at the bottom.

2
21
1
95
20,727
Diana Portales-Pérez retweeted
Eric Topol
@EricTopolSep 21
The potential to predict breast and prostate cancer up to 8 years before it is diagnosed from blood cell-free DNA methylation patterns cell.com/cell-genomics/fullt…

Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up...

Cheng et al. profile genome-wide cfDNA methylation in archived, prospectively collected plasma sampled 2 weeks to 9 years before breast or prostate cancer diagnosis. Regulatory-element signatures...

cell.com
16
196
14
749
54,622
Diana Portales-Pérez retweeted
PNASNews@PNASNewsSep 8
New research from @theNASciences and @theNAMedicine member Stanley Cohen and colleagues describes a microvesicle-based platform that delivers gene-silencing RNA, a step toward improving RNA-based therapeutics. In @PNASNexus: ow.ly/fRs550ZKNBi
Diagram and graphs showing how engineered microvesicles package gene-silencing RNA. Results demonstrate that TAR–Tat interactions and DICER1 mutation enhance RNA loading into microvesicles.

ALT Diagram and graphs showing how engineered microvesicles package gene-silencing RNA. Results demonstrate that TAR–Tat interactions and DICER1 mutation enhance RNA loading into microvesicles.

1
6
3,220
Load more